Morrison et al. found that mTORC2 signaling drives AKT-dependent tumor progression in HER2-amplified breast cancer, and mTORC1/2 dual kinase inhibitors reduce the survival of AKT-dependent HER2-amplified cells [85]. Here, ERBB2 is linked to breast carcinoma.